Notably, a recent investigation assessing potential long-term on-target effects of PCSK9 inhibitors explored the relationship between an LDL-C-lowering variant in the PCSK9 gene and clinical outcomes in the UK Biobank, revealing a previously unrecognized association between this variant and an elevated risk of peptic ulcer disease [20]. Here, PCSK9 is linked to peptic ulcer disease.